DigestRedComo funciona
Red
/
Empresas
Pr
No verificado

Prilenia Therapeutics B.V.

Sobre qué escribimos

BiotecnologíaFarmacéuticaIndustriaMedicina - VariosSalud

14 Comunicados de prensa

Ver todos los comunicados de prensa
08/09/2026
Multimedia
Mercado laboral
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Prilenia Appoints Frederick (Rick) Munschauer, MD, FAAN, as Chief Medical Officer
Fuente
Prilenia Therapeutics B.V.
Editor
Business Wire
1.00
0
07/07/2026
Prilenia and Ferrer Announce Initiation of the Confirmatory PRECISE-HD Study of Pridopidine in Huntington’s Disease
Fuente
Prilenia Therapeutics B.V.
Editor
Business Wire
1.00
0
26/05/2026
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Mercado laboral
Voluntariado/Solidaridad/ONGs
Industria
Prilenia Donates Clinical Trial Datasets to CHDI Foundation to Advance Huntington's Disease Research
Fuente
Prilenia Therapeutics B.V.
Editor
Business Wire
1.00
0
28/04/2026
Prilenia Appoints Dr. Elisabeth Leiderman as Chief Financial Officer
Fuente
Prilenia Therapeutics B.V.
Editor
Business Wire
1.00
0
30/03/2026
Multimedia
Mercado laboral
Industria
Salud
Higiene alimentaria
Sanidad
Medicina - Varios
Farmacéutica
Biotecnología
Prilenia and Ferrer Announce First Participant Enrolled in the “PREVAiLS” Phase 3 Study of Pridopidine in ALS
Fuente
Prilenia Therapeutics B.V.
Editor
Business Wire
1.00
0
11/12/2025
Multimedia
Industria
Ciencia
Higiene alimentaria
Medicina - Varios
Biotecnología
Salud
Farmacéutica
Sanidad
Prilenia and Ferrer Announce FDA Clearance to Start the “PREVAiLS” Pivotal Phase 3 Study with Pridopidine in ALS
Fuente
Prilenia Therapeutics B.V.
Editor
Business Wire
1.00
0
10/10/2025
Prilenia and Ferrer to Share New Data and Analyses of Pridopidine’s Impact on Huntington’s Disease at the Huntington Study Group (HSG) Congress
Fuente
Prilenia Therapeutics B.V.
Editor
Business Wire
1.00
0
06/10/2025
Multimedia
Ciencia
Medicina - Varios
Biotecnología
Sanidad
Salud
Farmacéutica
Industria
Pridopidine Pivotal Phase 3 ALS Study Unveiled at NEALS 2025 Annual Meeting
Fuente
Prilenia Therapeutics B.V.
Editor
Business Wire
1.00
0
05/09/2025
Multimedia
Biotecnología
Farmacéutica
Libros/Industria editorial
Sanidad
Salud
Comunicación
Medicina - Varios
Análisis de Mercados
Industria
Nature Medicine Publishes Phase 3 Data on Pridopidine in Early-Stage Huntington’s Disease, Highlighting Impact on Clinical Progression
Fuente
Prilenia Therapeutics B.V.
Editor
Business Wire
1.00
0
25/07/2025
Multimedia
Salud
Ciencia
Farmacéutica
Biotecnología
Industria
Prilenia and Ferrer Provide Update on European Regulatory Process for Pridopidine in Huntington’s Disease
Fuente
Prilenia Therapeutics B.V.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0